RCE
RCE Technologies is a pre-commercial med-tech company developing the Infrasensor, a wrist-worn wearable that uses proprietary mid-infrared spectroscopy and machine learning to detect early stages of severe heart attacks non-invasively, targeting hospital emergency departments, urgent care, and EMS.
- Company typePrivate
- Founded2018
- HeadquartersCarlsbad, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RCE does
RCE Technologies, Inc. is a pre-commercial medical technology company developing the Infrasensor, a wrist-worn wearable device that uses proprietary mid-infrared (MIR) spectroscopy combined with deep learning to detect early stages of severe coronary artery occlusion non-invasively. The device captures transdermal derived infrared spectrophotometric (TDIS) waveforms through the skin, processes them via proprietary ML algorithms, and delivers a cardiac assessment in approximately three minutes without the need for an invasive blood draw. RCE is pursuing FDA de novo pre-market clearance, with a pivotal study in Emergency Departments initiated in 2025 and FDA presubmission already completed.
The company's core technology rests on four issued US patents covering infrared sensor architecture, cardiac monitoring methods, and the wearable form factor, supported by a proprietary clinical dataset of 840+ patients enrolled across 10 US hospital sites. RCE's clinical evidence has been validated through publication in Nature Communications Medicine and the European Heart Journal, and through presentations at the American College of Cardiology Late Breaking Clinical Trials. The company's Scientific Advisory Board includes KOL cardiologists from leading academic centers (Baylor College of Medicine, Rutgers Robert Wood Johnson, and others), and its leadership includes a Chief Medical Officer with prior service as Senior Medical Officer at the FDA's Digital Health Center of Excellence.
RCE's go-to-market is sales-led and clinically validated, initially targeting Emergency Departments, urgent care facilities, and EMS/ambulance services, with secondary use cases in pharmaceutical cardiovascular drug trials and at-home monitoring of high-risk CAD patients. The company has secured a first commercial Letter of Intent, but remains pre-revenue. Future expansion includes the Infrasensor-home consumer wearable and licensing its AI sensor technology for integration into existing patch and watch-based platforms. The company is headquartered in Carlsbad, California, was founded in 2018, and has completed accelerator programs at TMCx and Cedars-Sinai.
RCE firmographics
Firmographics- Name
- RCE
- Legal name
- RCE Technologies, Inc.
- Website
- https://rce.ai
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RCE Technologies is a pre-commercial med-tech company developing the Infrasensor, a wrist-worn wearable that uses proprietary mid-infrared spectroscopy and machine learning to detect early stages of severe heart attacks non-invasively, targeting hospital emergency departments, urgent care, and EMS.
- Ownership category
- akta.pro rank
RCE industry classification
Industry- Product category
- Cardiac Diagnostic Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB)
- akta.pro secondary industries
- Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Cardiology Telemedicine Platforms (HLALAGAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI)
Keywords
Where RCE is headquartered
LocationHeadquarters
- HQ city
- Carlsbad
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RCE business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Wearable Device Sales: Pre-commercial stage. Revenue expected from sale of wrist-worn wearable devices with integrated infrared sensors for cardiac monitoring.
Go-to-market motion3 records
Marketing channels5 records
RCE product offering
Product offeringCore offering
RCE Technologies develops and is commercializing the Infrasensor, a wrist-worn wearable medical device that combines proprietary mid-infrared spectroscopy sensors with cloud-based machine learning to non-invasively measure cardiac biomarkers transdermally and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. The investigational device is targeted at hospital emergency departments, urgent care centers, EMS providers, pharmaceutical trial sponsors, and high-risk at-home CAD patients, with FDA de novo pre-market clearance currently in process.
Differentiator
Problem solved
Functional benefit
Brands
- Infrasensor: A non-invasive wrist-worn device for detection of high-grade obstructive Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) using infrared spectroscopy technology.
Products and services
- Infrasensor A wrist-worn wearable medical device that uses proprietary mid-infrared spectroscopy sensors and cloud-based machine learning to non-invasively analyze Transdermal Derived Infrared Spectrophotometric (TDIS) waveforms from the skin and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. Currently an investigational device used for research only, pending FDA de novo pre-market clearance; intended for hospital emergency departments, urgent care centers, EMS providers, and pharmaceutical trial sponsors.
Quantifiable outcome
- 3-minute non-invasive cardiac assessment
- +1 more outcomes
Companies that use RCE
Customer profileSegments5 records
Ideal customer profiles4 records
RCE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
RCE partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- American Heart AssociationflagshipAmerican Heart Association is a key strategic partner and has recognized RCE as a Health Tech Winner. The partnership provides credibility in the cardiovascular health space and access to AHA's network and resources.
- Cedars-Sinai AcceleratorcoreRCE participated in the Cedars-Sinai Accelerator program, gaining access to clinical expertise, hospital network validation opportunities, and mentorship from healthcare industry veterans.
- Texas Medical Center (TMCx)coreRCE completed the TMCx accelerator program, providing access to the world's largest medical complex for clinical validation and healthcare system partnerships.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
RCE competitors and assessment
Company assessmentDirect peers
- AliveCor: AliveCor makes KardiaMobile, a clinical-grade single-lead ECG device for at-home and point-of-care cardiac rhythm assessment. It is the closest direct peer because it sells a consumer/clinical hardware device using AI/ML to detect cardiac abnormalities (arrhythmias) outside the hospital, overlapping with RCE's wrist-worn AI cardiac biomarker platform in use case and customer profile.
- iRhythm Technologies: iRhythm's Zio long-term ambulatory ECG patch and AI-based arrhythmia detection platform is a direct clinical cardiology diagnostic competitor. It shares RCE's profile of an AI-enabled wearable cardiac diagnostic with FDA clearance, hospital channel sales, and reimbursement-driven economics.
- Eko Health: Eko combines digital stethoscopes with FDA-cleared AI algorithms (including for cardiac biomarkers and murmurs) for clinicians in primary care and ED settings. It competes on the same problem RCE solves, using a different sensor modality, and shares a hospital sales motion plus AI/ML device regulatory playbook.
- HeartFlow: HeartFlow provides AI-driven non-invasive cardiac diagnostics (CT-derived FFR) for coronary artery disease assessment. It is comparable as an AI-first, non-invasive alternative to invasive cardiac diagnostics sold into the same cardiology customer base as RCE.
Broad incumbents
- Abbott Diagnostics: Abbott's ARCHITECT and Alinity high-sensitivity troponin assays plus its i-STAT point-of-care troponin platform dominate the ED cardiac biomarker market that RCE would enter. Comparable as the incumbent whose installed base, turnaround improvements, and hospital contracts RCE must displace or complement.
- Roche Diagnostics: Roche's Elecsys high-sensitivity troponin-T assays are the global standard for ED cardiac biomarker testing. Relevant as the entrenched competitor with deep hospital integration, continuous assay improvements, and clinical guideline endorsements that RCE must compete against.
- Siemens Healthineers: Siemens Healthineers markets Atellica and ADVIA Centaur high-sensitivity troponin-I assays and a broad hospital diagnostics portfolio. It is comparable as an incumbent cardiac biomarker vendor whose assay iteration cadence sets the competitive bar for RCE's launch.
- GE HealthCare: GE HealthCare's MUSE ECG management, inpatient telemetry/monitoring, and patient monitoring portfolio competes in the same hospital cardiology workflow RCE targets. Relevant as a broad incumbent with established hospital relationships and integrated cardiology IT platforms.
- Philips (Cardiac Monitoring): Philips sells cardiac telemetry, ECG, and acute care monitoring solutions into hospital systems globally. Comparable as a broad incumbent selling into the same cardiology and ED/ICU buyer, with established integration, training, and service infrastructure that RCE would need to match.
Emerging players
- Cleerly Health: Cleerly applies AI to cardiac CT imaging for plaque and stenosis assessment in coronary artery disease. It overlaps with RCE as an emerging AI-driven, non-invasive cardiology diagnostic targeting similar hospital and cardiology customers, though with an imaging rather than wearable sensor modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
RCE social profiles
Digital presenceRCE financial estimates
Financial estimateRevenue estimate
Valuation estimate
RCE leadership team
Management profileNumber of profiles
Profiles9 records
RCE funding detail
Funding detailFunding overview
Funding rounds6 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RCE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RCE
What does RCE do?
RCE Technologies develops and is commercializing the Infrasensor, a wrist-worn wearable medical device that combines proprietary mid-infrared spectroscopy sensors with cloud-based machine learning to non-invasively measure cardiac biomarkers transdermally and detect early stages of severe coronary artery occlusion (high-grade obstructive NSTE-ACS) in approximately three minutes. The investigational device is targeted at hospital emergency departments, urgent care centers, EMS providers, pharmaceutical trial sponsors, and high-risk at-home CAD patients, with FDA de novo pre-market clearance currently in process.
Is RCE a public or private company?
RCE is a private company. It is classified as venture growth investor backed and is currently operating.
When was RCE founded?
RCE was founded in 2018. It employs 1 to 10 people.
Where is RCE based?
RCE is headquartered in Carlsbad, United States, in the North America region.
How does RCE make money?
One revenue line is on record: wearable Device Sales.
Who are RCE's main competitors?
Direct peers on record are AliveCor, iRhythm Technologies, Eko Health and HeartFlow. Broad incumbents are Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, GE HealthCare and Philips (Cardiac Monitoring). Cleerly Health is listed as an emerging player.
Does RCE have an API?
No public API is recorded for RCE.
What industry is RCE in?
RCE's product category is Cardiac Diagnostic Medical Devices. Its primary akta.pro industry code is HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables), with a secondary code of HLALAFAA, Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity). Its NAICS code is 334510 and its SIC code is 3845.